WASHINGTON, D.C. – April 25, 2017 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Jan Holmgren with the 2017 Albert B. Sabin Gold Medal Award. Dr. Holmgren will be recognized for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.
Geneva, Switzerland – November 18, 2016 – Today, the Sabin Vaccine Institute (Sabin) begins its formal membership with the Coalition for Epidemic Preparedness Innovations (CEPI), as global health leaders gather in Geneva, Switzerland for the first meeting of CEPI’s Joint Coordination Group (JCG).
Vatican City – November 10, 2016 –Peter Hotez, M.D., Ph.D., president of the Sabin Vaccine Institute (Sabin) and director of the Sabin Product Development Partnership (Sabin PDP), today will help kick off the first-ever Vatican conference on neglected tropical diseases (NTDs) and rare diseases with a keynote address.
WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.
Statement of Dr. Peter Hotez, President of the Sabin Vaccine Institute and Director of its Product Development Partnership on the Group of 7 (G7) Summit, at which the leaders of Japan, the United States, the United Kingdom, Germany, Canada, Italy and France affirmed a commitment to neglected tropical diseases (NTDs).
WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.
WASHINGTON, D.C. — Feb. 8, 2016 — On Monday, the World Health Organization (WHO) Director-General, Dr. Margaret Chan, declared Zika a Public Health Emergency International Concern (PHEIC), because of growing concerns of the suspected association between Zika and the rise in detected cases of congenital malformations and neurological complications in newborn babies.
WASHINGTON, D.C. — January 13, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Kenneth Kelley, M.B.A., and Jordan Orange, M.D., Ph.D., to its Board of Trustees. Mr. Kelley is a Harvard Senior Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. Dr. Orange is chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the pediatrics department at Baylor College of Medicine.
WASHINGTON, D.C. — January 5, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees unanimously appointed Axel Hoos, M.D., Ph.D., to serve as chairman of the board, and Peter L. Thoren to serve as vice chairman. Both were appointed to interim positions in December 2014.
December 22, 2015 — The Philippines yesterday became the first Asian country to approve Sanofi Pasteur’s dengue vaccine, Dengvaxia®, marking the second time in less than one month that a dengue vaccine has been licensed for use in a country.